Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DORAL: Doravirine/Raltegravir Switch in HIV-1
NCT04513626Phase 2Recruiting
- Sponsor
- Centre de Recherches et d'Études sur la Pathologie Tropicale et le Sida
- Start
- Sep 2020
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of doravirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Centre de Recherches et d'Études sur la Pathologie Tropicale et le Sida. Started Sep 2020; status: recruiting.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04513626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04513626.